![[Tebubio Newsletter - Edition 2] Everything You Need, in One Place](https://www.tebubio.com/media/magefan_blog/Posts_2025/Newsletter_Banner_1500x300px_1_.png)
Tebubio Newsletter - Edition 2
Stay ahead in your research with your monthly Tebubio newsletter—your go-to source for innovative reagents, expert services, and insightful articles. Curated to bring you the most relevant products, services and knowledge resources, it helps you focus on what truly matters—your research.
Welcome to the Second Edition Of The Tebubio Newsletter
We’re back with another curated selection of scientific updates, expert resources, and product innovations designed to support your research. This month, we spotlight new insights in immunotherapy, oncology, cell and gene therapy, and RNA therapeutics —plus a look at our latest poster from AACR 2025!
We’re also proud to welcome DIVA Expertise to our catalogue, celebrate 30 years of Tebubio Germany, and share our first CSR Report, highlighting our commitment to responsible science and sustainability.
All in one place—to help you move your research forward, faster.
Event Of The Day
Empowering the Development of TCR 1 CAR-T Cells for Adoptive Cell Therapy
Join our live webinar with BPS Bioscience to discover next-generation tools to accelerate your adoptive cell therapy research, from primary human immune cells to advanced assays for target recognition and T cell activation. Join us to explore how to streamline your CAR and TCR engineering workflows with powerful, ready-to-use solutions.
Date: June 5, 2025
Time: 4:00 PM CEST
Speaker: Véronique Baron, PhD, BPS Bioscience
Meet The Tebubio Team Near You
Meet us at ELRIG - Therapeutic Oligonucleotides 2025 Congress
Join us at the next Therapeutic Oligonucleotides 2025 congress organised by ELRIG, on May 14–15, 2025, at AstraZeneca’s R&D site in Gothenburg, Sweden.
Let's connect with our colleague Charlotte Adler to discuss about your projects and discover how Tebubio can support your Therapeutic Oligonucleotides development.
Date: May 14-15, 2025
Immunotherapy
Struggling to scale T or NK cell therapies effectively?
Discover how Nanotein platforms offer an innovative solution by ensuring robust, scalable cell expansion and activation.
Learn how these cutting-edge tools can help streamline your research and accelerate the development of effective immunotherapies.
Oncology
Unlock the Potential of Gamma Delta T Cells in Cancer Therapy
Gamma Delta (γδ) T cells are emerging as powerful players in cancer immunotherapy, thanks to their unique ability to recognize and destroy tumor cells.
Discover how BPS Bioscience supports your research with innovative tools to explore γδ TCR-based therapeutic strategies.
Cell & Gene Therapy
Is Alzheimer’s-linked Amyloid-β Driving Neural Ageing
New findings show that Amyloid-β not only accelerates cell senescence but also suppresses SIRT1 in human neural stem cells—two key factors in neurodegeneration and ageing.
This article explores the mechanisms involved and highlights senescence-associated β-galactosidase as a biomarker worth tracking.
RNA Therapeutics
Can the Right mRNA Design Boost Your Therapeutic Success?
Explore how CleanCap® technology and minimal UTRs are reshaping mRNA stability and translation—key factors for effective mRNA therapeutics.
This blog offers expert insights and practical takeaways to help you optimise your mRNA constructs for maximum impact.
Tebubio Contract Research Services
New Poster Now Available: Advancing RNA Delivery in Oncology
Presented at AACR 2025, our latest poster showcases how Tebubio’s Contract Research Services (CRS) platforms enables real-time tracking of RNA delivery using fluorescent lipid nanoparticles.
Developped in collaboration with Echelon Biosciences and patient-derived models, this work reflects our CRS expertise in supporting oncology research from RNA design to in vitro validation.
Knowledge Resources
New Partnership
Now Available: High-Quality Human Samples from DIVA Expertise
We’re excited to welcome DIVA Expertise to the Tebubio catalogue! Specialising in adipose and skin tissues, they provide prequalified, clinically annotated human biological samples—ready to support your R&D, from preclinical models to cell-based assays.
Quality-controlled, serology-tested, and available for rapid delivery.
Monthly Highlight
Celebrating 30 Years of Tebubio Germany!
This year marks a major milestone — 30 years since the opening of our German office! Over the past three decades, Tebubio Germany has grown alongside the scientific community, providing trusted solutions and local support to researchers across the region.
We're grateful to everyone who has contributed to this success story and look forward to many more years of shared progress and discovery.
Building A Sustainable Future Together
Tebubio Releases its first CSR (Corporate Social Responsibility) Report!
This report outlines our commitments and actions across key areas such as environmental sustainability, ethical business conduct, responsible sourcing, and employee well-being. It reflects both the values that drive our organization and the progress we have made so far, while also presenting our long-term ambitions.
Stay Ahead in Your Research
Subscribe to our monthly newsletter for the latest breakthroughs, expert insights, and exclusive updates in key research areas.